Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 6/20 | 1.00 |
| ▸ | CYP1B1 | Q16678 | 6/20 | 1.00 |
| ▸ | ALOX5 | P09917 | 6/20 | 1.00 |
| ▸ | NQO2 | P16083 | 5/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 4/20 | 1.00 |
| ▸ | TTR | P02766 | 3/20 | 1.00 |
| ▸ | ABL1 | P00519 | 3/20 | 1.00 |
| ▸ | BCR | P11274 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 2/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | RAB9A | P51151 | 1/20 | 1.00 |
| ▸ | GFER | P55789 | 1/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pterostilbene SCHEMBL28222684 | 1.00 | CYP1A1 (1.00) | CYP1A1CYP1B1ALOX5NQO2PTGS2 | |
| Pterostilbene SCHEMBL20063 | 1.00 | CYP1A1 (1.00) | CYP1A1CYP1B1ALOX5NQO2PTGS2 | |
| Pterostilbene SCHEMBL3545782 | 1.00 | CYP1A1 (1.00) | CYP1A1CYP1B1ALOX5NQO2PTGS2 | |
| SCHEMBL562335 | 0.94 | CYP1A1 (1.00) | CYP1A1CYP1B1ALOX5NQO2PTGS2 | |
| SCHEMBL562336 | 0.94 | CYP1A1 (1.00) | CYP1A1CYP1B1ALOX5NQO2PTGS2 | |
| SCHEMBL30475363 | 0.94 | CYP1A1 (1.00) | CYP1A1CYP1B1ALOX5NQO2PTGS2 | |
| Pterostilbene SCHEMBL3476941 | 0.93 | NQO2 (0.86) | CYP1A1CYP1B1ALOX5NQO2PTGS2 | |
| Pterostilbene SCHEMBL3476943 | 0.93 | NQO2 (0.86) | CYP1A1CYP1B1ALOX5NQO2PTGS2 | |
| SCHEMBL25328598 | 0.92 | CYP1A1 (0.86) | CYP1A1CYP1B1ALOX5NQO2PTGS2 | |
| SCHEMBL12535853 | 0.89 | PTGS2 (0.80) | CYP1A1CYP1B1ALOX5NQO2PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 507 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024211130-A1 | METHODS FOR MODIFYING MEIOTIC RECOMBINATION IN PLANTS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2024-10-10 | — | — | WO | claimed |
| US-20240263203-A1 | RECOMBINANT HOST CELLS WITH IMPROVED PRODUCTION OF TETRAKETIDE DERIVATIVES | IPTECTOR ASSETS APS (DK) | 2024-08-08 | — | — | US | claimed |
| WO-2024124467-A1 | HYDROXYSTILBENE COMPOUND OINTMENT, USE THEREOF, AND PREPARATION METHOD THEREFOR | 科笛生物医药(无锡)有限公司 | 2024-06-20 | — | — | WO | claimed |
| WO-2023164606-A1 | COMPOUNDS FOR MODIFYING MEIOTIC RECOMBINATION AND METHODS RELATING THERETO | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2023-08-31 | — | — | WO | claimed |
| WO-2023064318-A1 | BIPHASIC COMPOSITIONS COMPRISING ONE OR BOTH OF CARBONATE AND PHOSPHATE | Natural Extraction Systems, LLC (US) | 2023-04-20 | — | — | WO | claimed |
| EP-4142751-A1 | FIBROBLAST MEDIATED EXPANSION AND AUGMENTATION OF IMMUNE REGULATORY CELLS FOR TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) | Figene, LLC (US) | 2023-03-08 | — | — | EP | claimed |
| EP-3906301-A1 | RECOMBINANT HOST CELLS WITH IMPROVED PRODUCTION OF TETRAKETIDE DERIVATIVES | Barrit Sarl (FR) | 2021-11-10 | — | — | EP | claimed |
| US-20210338558-A1 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | FABIUS BIOTECHNOLOGY (US) | 2021-11-04 | — | — | US | claimed |
| CN-111635389-A | Hydrogen peroxide responsive compound for imaging and therapy and synthesis method thereof | 中国人民解放军陆军军医大学 | 2020-09-08 | — | — | CN | claimed |
| WO-2020141230-A1 | RECOMBINANT HOST CELLS WITH IMPROVED PRODUCTION OF TETRAKETIDE DERIVATIVES | BARRIT SARL (FR) | 2020-07-09 | — | — | WO | claimed |
| WO-2010111719-A2 | MELANOGENESIS INHIBITION BY 3, 5-DIMETHOXY-4'-HYDROXYSTILBENES AND COSMECEUTICAL COMPOSITIONS THEREOF | SAMI LABS LIMITED (IN) | 2010-09-30 | — | — | WO | claimed |
| US-20100240767-A1 | Melanogenesis inhibitiuon by 3,5-dimethoxy-4'-hydroxystilbenes and cosmeceutical compositions thereof | SAMI LABS LTD (IN) | 2010-09-23 | — | — | US | claimed |
| US-20100204179-A1 | Resveratrol complex and process for the preperation | UNIÃO BRASILEIRA DE EDUCAÇÃO E ASSISTÊNCIA - MANTENEDORA DA PUCRS (BR) | 2010-08-12 | — | — | US | claimed |
| EP-2178525-A1 | RESVERATROL COMPLEX AND PROCESS FOR THE PREPERATION | União Brasileira De Educação E Assistência - Mantenedora Da Pucrs (BR) | 2010-04-28 | — | — | EP | claimed |
| US-7705188-B2 | Structural modification of resveratrol: sodium resverastatin phosphate | Arizona Board of Regents, a body corporate of the State of Arizona, Acting for and on Behalf of the Arizona State University (US) | 2010-04-27 | — | — | US | claimed |
| WO-2009118338-A2 | USE OF A POLYPHENOLIC TYPE COMPOUND FOR PREVENTING OR TREATING A POLYGLUTAMINE EXPANSION NEURODEGENERATIVE DISEASE | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2009-10-01 | — | — | WO | claimed |
| WO-2009012551-A1 | RESVERATROL COMPLEX AND PROCESS FOR THE PREPERATION | UNIÄO BRASILEIRA DE EDUCAÇAO E ASSITENCIA-MANTENEDORA DA PUCRS (BR) | 2009-01-29 | — | — | WO | claimed |
| US-20080166304-A1 | Inactivation of Microorganisms With Multidrug Resistance Inhibitors and Phenothiaziniums | THE GENERAL HOSPITAL CORPOARTION (US) | 2008-07-10 | — | — | US | claimed |
| US-20080139650-A1 | Fungicidally Active Polymer Dispersions And Use Thereof | CELANESE EMULSIONS GMBH (DE) | 2008-06-12 | — | — | US | claimed |
| WO-2006034219-A2 | INACTIVATION OF MICROORGANISMS WITH MULTIDRUG RESISTANCE INHIBITORS AND PHENOTHIAZINIUMS | THE GENERAL HOSPITAL CORPORATION (US) | 2006-03-30 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240767-A1 | Melanogenesis inhibitiuon by 3,5-dimethoxy-4'-hydroxystilbenes and cosmeceutical compositions thereof | TYR, MC1R, MITF | CYP1A1 620/4885CYP1B1 176/4885ALOX5 171/4885 |
| US-20080139650-A1 | Fungicidally Active Polymer Dispersions And Use Thereof | CBR3, CBR1, CYP3A4 | CYP1A1 5/4885CYP1B1 4/4885ALOX5 251/4885 |
| US-20210338558-A1 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | COL14A1, COL2A1, COL1A1 | CYP1A1 2414/4885CYP1B1 2275/4885ALOX5 4281/4885 |
| US-20100204179-A1 | Resveratrol complex and process for the preperation | SI, GPR119, GYS1 | CYP1A1 958/4885CYP1B1 1425/4885ALOX5 3037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.